Literature DB >> 15925492

The epidemiology of panic disorder and agoraphobia in Europe.

R D Goodwin1, C Faravelli, S Rosi, F Cosci, E Truglia, R de Graaf, H U Wittchen.   

Abstract

A literature search, in addition to expert survey, was performed to estimate the size and burden of panic disorder in the European Union (EU). Epidemiologic data from EU countries were critically reviewed to determine the consistency of prevalence estimates across studies and to identify the most pressing questions for future research. A comprehensive literature search focusing on epidemiological studies in community and clinical settings in European countries since 1980 was conducted (Medline, Web of Science, Psychinfo). Only studies using established diagnostic instruments on the basis of DSM-III-R or DSM-IV, or ICD-10 were considered. Thirteen studies from a total of 14 countries were identified. Epidemiological findings are relatively consistent across the EU. The 12-month prevalence of panic disorder and agoraphobia without history of panic were estimated to be 1.8% (0.7-2.2) and 1.3% (0.7-2.0) respectively across studies. Rates are twice as high in females and age of first onset for both disorders is in adolescence or early adulthood. In addition to comorbidity with agoraphobia, panic disorder is strongly associated with other anxiety disorders, and a wide range of somatoform, affective and substance use disorders. Even subclinical forms of panic disorder (i.e., panic attacks) are associated with substantial distress, psychiatric comorbidity and functional impairment. In general health primary care settings, there appears to be substantial underdiagnosis and undertreatment of panic disorder. Moreover, panic disorder and agoraphobia are poorly recognized and rarely treated in mental health settings, despite high health care utilization rates and substantial long-term disability.

Entities:  

Mesh:

Year:  2005        PMID: 15925492     DOI: 10.1016/j.euroneuro.2005.04.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  40 in total

1.  Panic disorder.

Authors:  C Barr Taylor
Journal:  BMJ       Date:  2006-04-22

2.  Rgs 2 gene polymorphisms as modulators of anxiety in humans?

Authors:  A Leygraf; C Hohoff; C Freitag; S A G Willis-Owen; P Krakowitzky; J Fritze; P Franke; B Bandelow; R Fimmers; J Flint; J Deckert
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 3.  The Deakin/Graeff hypothesis: focus on serotonergic inhibition of panic.

Authors:  Evan D Paul; Philip L Johnson; Anantha Shekhar; Christopher A Lowry
Journal:  Neurosci Biobehav Rev       Date:  2014-03-21       Impact factor: 8.989

4.  Onset and risk factors for anxiety and depression during the first 2 years after lung transplantation.

Authors:  Mary Amanda Dew; Andrea F DiMartini; Annette J DeVito Dabbs; Kristen R Fox; Larissa Myaskovsky; Donna M Posluszny; Galen E Switzer; Rachelle A Zomak; Robert L Kormos; Yoshiya Toyoda
Journal:  Gen Hosp Psychiatry       Date:  2012-01-14       Impact factor: 3.238

5.  Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys.

Authors:  Peter de Jonge; Annelieke M Roest; Carmen C W Lim; Silvia E Florescu; Evelyn J Bromet; Dan J Stein; Meredith Harris; Vladimir Nakov; Jose Miguel Caldas-de-Almeida; Daphna Levinson; Ali O Al-Hamzawi; Josep Maria Haro; Maria Carmen Viana; Guilherme Borges; Siobhan O'Neill; Giovanni de Girolamo; Koen Demyttenaere; Oye Gureje; Noboru Iwata; Sing Lee; Chiyi Hu; Aimee Karam; Jacek Moskalewicz; Viviane Kovess-Masfety; Fernando Navarro-Mateu; Mark Oakley Browne; Marina Piazza; José Posada-Villa; Yolanda Torres; Margreet L Ten Have; Ronald C Kessler; Kate M Scott
Journal:  Depress Anxiety       Date:  2016-10-24       Impact factor: 6.505

Review 6.  Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks.

Authors:  Philip L Johnson; Lauren M Federici; Anantha Shekhar
Journal:  Neurosci Biobehav Rev       Date:  2014-08-15       Impact factor: 8.989

Review 7.  An animal model of panic vulnerability with chronic disinhibition of the dorsomedial/perifornical hypothalamus.

Authors:  Philip L Johnson; Anantha Shekhar
Journal:  Physiol Behav       Date:  2012-03-26

8.  Hippocampal hyperexcitability underlies enhanced fear memories in TgNTRK3, a panic disorder mouse model.

Authors:  Mónica Santos; Davide D'Amico; Ornella Spadoni; Alejandro Amador-Arjona; Oliver Stork; Mara Dierssen
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

9.  Association analysis of Rgs7 variants with panic disorder.

Authors:  Christa Hohoff; Anna Neumann; Katharina Domschke; Christian Jacob; Wolfgang Maier; Jürgen Fritze; Borwin Bandelow; Petra Krakowitzky; Matthias Rothermundt; Volker Arolt; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2008-09-02       Impact factor: 3.575

10.  A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Authors:  Mark Pollack; Richard Mangano; Richard Entsuah; Evan Tzanis; Naomi M Simon; Ying Zhang
Journal:  Psychopharmacology (Berl)       Date:  2007-06-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.